Interaction of milrinone with extracorporeal life support
Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown. Ex vivo ECMO and CRR...
Gespeichert in:
| Veröffentlicht in: | The Journal of extra-corporeal technology 2024-12, Vol.56 (4), p.167-173 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 173 |
|---|---|
| container_issue | 4 |
| container_start_page | 167 |
| container_title | The Journal of extra-corporeal technology |
| container_volume | 56 |
| creator | Whelan, Aviva J Mim, Sabiha Hunt, J Porter McKnite, Autumn M Green, Danielle J Imburgia, Carina E Momper, Jeremiah D Stitt, Gideon Watt, Kevin M |
| description | Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.
Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.
Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.
Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness. |
| doi_str_mv | 10.1051/ject/2024014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11661780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_60fab62910fa449ba95eb8532c1020e6</doaj_id><sourcerecordid>3147694872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2534-61b01bb67108b51cd36efecac1c2bbc04a25cceaa3a8125f93203f124a43d3dc3</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhi1ERbctN84oRw6Ezvgr8QmhCspKlbi0Z8t2Jq1X2Xixs3z8e1x2qehpNJ5Hj2f0MvYG4QOCwssNheWSA5eA8gVbcaNN2xsNL9kKgPO2Qv0pOytlA6ARBL5ip8J0oFQPK2bW80LZhSWmuUljs41TjnOaqfkZl4eGfi11mPIuZXJTM8WRmrLf1Xa5YCejmwq9PtZzdvfl8-3V1_bm2_X66tNNG7gSstXoAb3XHULvFYZBaBopuICBex9AOq5CIOeE65Gr0QgOYkQunRSDGII4Z-uDd0huY3c5bl3-bZOL9u9DyvfW5SWGiayG0XnNDdYqpfHOKPK9EjwgcCBdXR8Prt3eb2kINNfzpmfS55M5Ptj79MMiao1dD9Xw7mjI6fueymK3sQSaJjdT2hcrUHbayL7jFX1_QENOpWQan_5BsI_R2cfo7DG6ir_9f7cn-F9W4g8GkpWp</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3147694872</pqid></control><display><type>article</type><title>Interaction of milrinone with extracorporeal life support</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Whelan, Aviva J ; Mim, Sabiha ; Hunt, J Porter ; McKnite, Autumn M ; Green, Danielle J ; Imburgia, Carina E ; Momper, Jeremiah D ; Stitt, Gideon ; Watt, Kevin M</creator><creatorcontrib>Whelan, Aviva J ; Mim, Sabiha ; Hunt, J Porter ; McKnite, Autumn M ; Green, Danielle J ; Imburgia, Carina E ; Momper, Jeremiah D ; Stitt, Gideon ; Watt, Kevin M</creatorcontrib><description>Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.
Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.
Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.
Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.</description><identifier>ISSN: 0022-1058</identifier><identifier>ISSN: 2969-8960</identifier><identifier>EISSN: 2969-8960</identifier><identifier>DOI: 10.1051/ject/2024014</identifier><identifier>PMID: 39705580</identifier><language>eng</language><publisher>France: EDP Sciences</publisher><subject>continuous renal replacement therapy (crrt) ; Continuous Renal Replacement Therapy - methods ; extracorporeal life support (ecls) ; extracorporeal membrane oxygenation (ecmo) ; Extracorporeal Membrane Oxygenation - methods ; Humans ; milrinone ; Milrinone - administration & dosage ; Original</subject><ispartof>The Journal of extra-corporeal technology, 2024-12, Vol.56 (4), p.167-173</ispartof><rights>The Author(s), published by EDP Sciences, 2024.</rights><rights>The Author(s), published by EDP Sciences, 2024 2024 The Author(s)</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2534-61b01bb67108b51cd36efecac1c2bbc04a25cceaa3a8125f93203f124a43d3dc3</cites><orcidid>0000-0001-7985-2991 ; 0000-0001-5269-214X ; 0000-0003-3503-8124 ; 0000-0001-8968-3183 ; 0009-0005-9359-8527</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661780/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661780/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39705580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Whelan, Aviva J</creatorcontrib><creatorcontrib>Mim, Sabiha</creatorcontrib><creatorcontrib>Hunt, J Porter</creatorcontrib><creatorcontrib>McKnite, Autumn M</creatorcontrib><creatorcontrib>Green, Danielle J</creatorcontrib><creatorcontrib>Imburgia, Carina E</creatorcontrib><creatorcontrib>Momper, Jeremiah D</creatorcontrib><creatorcontrib>Stitt, Gideon</creatorcontrib><creatorcontrib>Watt, Kevin M</creatorcontrib><title>Interaction of milrinone with extracorporeal life support</title><title>The Journal of extra-corporeal technology</title><addtitle>J Extra Corpor Technol</addtitle><description>Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.
Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.
Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.
Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.</description><subject>continuous renal replacement therapy (crrt)</subject><subject>Continuous Renal Replacement Therapy - methods</subject><subject>extracorporeal life support (ecls)</subject><subject>extracorporeal membrane oxygenation (ecmo)</subject><subject>Extracorporeal Membrane Oxygenation - methods</subject><subject>Humans</subject><subject>milrinone</subject><subject>Milrinone - administration & dosage</subject><subject>Original</subject><issn>0022-1058</issn><issn>2969-8960</issn><issn>2969-8960</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkU1v1DAQhi1ERbctN84oRw6Ezvgr8QmhCspKlbi0Z8t2Jq1X2Xixs3z8e1x2qehpNJ5Hj2f0MvYG4QOCwssNheWSA5eA8gVbcaNN2xsNL9kKgPO2Qv0pOytlA6ARBL5ip8J0oFQPK2bW80LZhSWmuUljs41TjnOaqfkZl4eGfi11mPIuZXJTM8WRmrLf1Xa5YCejmwq9PtZzdvfl8-3V1_bm2_X66tNNG7gSstXoAb3XHULvFYZBaBopuICBex9AOq5CIOeE65Gr0QgOYkQunRSDGII4Z-uDd0huY3c5bl3-bZOL9u9DyvfW5SWGiayG0XnNDdYqpfHOKPK9EjwgcCBdXR8Prt3eb2kINNfzpmfS55M5Ptj79MMiao1dD9Xw7mjI6fueymK3sQSaJjdT2hcrUHbayL7jFX1_QENOpWQan_5BsI_R2cfo7DG6ir_9f7cn-F9W4g8GkpWp</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Whelan, Aviva J</creator><creator>Mim, Sabiha</creator><creator>Hunt, J Porter</creator><creator>McKnite, Autumn M</creator><creator>Green, Danielle J</creator><creator>Imburgia, Carina E</creator><creator>Momper, Jeremiah D</creator><creator>Stitt, Gideon</creator><creator>Watt, Kevin M</creator><general>EDP Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7985-2991</orcidid><orcidid>https://orcid.org/0000-0001-5269-214X</orcidid><orcidid>https://orcid.org/0000-0003-3503-8124</orcidid><orcidid>https://orcid.org/0000-0001-8968-3183</orcidid><orcidid>https://orcid.org/0009-0005-9359-8527</orcidid></search><sort><creationdate>202412</creationdate><title>Interaction of milrinone with extracorporeal life support</title><author>Whelan, Aviva J ; Mim, Sabiha ; Hunt, J Porter ; McKnite, Autumn M ; Green, Danielle J ; Imburgia, Carina E ; Momper, Jeremiah D ; Stitt, Gideon ; Watt, Kevin M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2534-61b01bb67108b51cd36efecac1c2bbc04a25cceaa3a8125f93203f124a43d3dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>continuous renal replacement therapy (crrt)</topic><topic>Continuous Renal Replacement Therapy - methods</topic><topic>extracorporeal life support (ecls)</topic><topic>extracorporeal membrane oxygenation (ecmo)</topic><topic>Extracorporeal Membrane Oxygenation - methods</topic><topic>Humans</topic><topic>milrinone</topic><topic>Milrinone - administration & dosage</topic><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Whelan, Aviva J</creatorcontrib><creatorcontrib>Mim, Sabiha</creatorcontrib><creatorcontrib>Hunt, J Porter</creatorcontrib><creatorcontrib>McKnite, Autumn M</creatorcontrib><creatorcontrib>Green, Danielle J</creatorcontrib><creatorcontrib>Imburgia, Carina E</creatorcontrib><creatorcontrib>Momper, Jeremiah D</creatorcontrib><creatorcontrib>Stitt, Gideon</creatorcontrib><creatorcontrib>Watt, Kevin M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>The Journal of extra-corporeal technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Whelan, Aviva J</au><au>Mim, Sabiha</au><au>Hunt, J Porter</au><au>McKnite, Autumn M</au><au>Green, Danielle J</au><au>Imburgia, Carina E</au><au>Momper, Jeremiah D</au><au>Stitt, Gideon</au><au>Watt, Kevin M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interaction of milrinone with extracorporeal life support</atitle><jtitle>The Journal of extra-corporeal technology</jtitle><addtitle>J Extra Corpor Technol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>56</volume><issue>4</issue><spage>167</spage><epage>173</epage><pages>167-173</pages><issn>0022-1058</issn><issn>2969-8960</issn><eissn>2969-8960</eissn><abstract>Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.
Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.
Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.
Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.</abstract><cop>France</cop><pub>EDP Sciences</pub><pmid>39705580</pmid><doi>10.1051/ject/2024014</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7985-2991</orcidid><orcidid>https://orcid.org/0000-0001-5269-214X</orcidid><orcidid>https://orcid.org/0000-0003-3503-8124</orcidid><orcidid>https://orcid.org/0000-0001-8968-3183</orcidid><orcidid>https://orcid.org/0009-0005-9359-8527</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1058 |
| ispartof | The Journal of extra-corporeal technology, 2024-12, Vol.56 (4), p.167-173 |
| issn | 0022-1058 2969-8960 2969-8960 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11661780 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | continuous renal replacement therapy (crrt) Continuous Renal Replacement Therapy - methods extracorporeal life support (ecls) extracorporeal membrane oxygenation (ecmo) Extracorporeal Membrane Oxygenation - methods Humans milrinone Milrinone - administration & dosage Original |
| title | Interaction of milrinone with extracorporeal life support |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A23%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interaction%20of%20milrinone%20with%20extracorporeal%20life%20support&rft.jtitle=The%20Journal%20of%20extra-corporeal%20technology&rft.au=Whelan,%20Aviva%20J&rft.date=2024-12&rft.volume=56&rft.issue=4&rft.spage=167&rft.epage=173&rft.pages=167-173&rft.issn=0022-1058&rft.eissn=2969-8960&rft_id=info:doi/10.1051/ject/2024014&rft_dat=%3Cproquest_doaj_%3E3147694872%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3147694872&rft_id=info:pmid/39705580&rft_doaj_id=oai_doaj_org_article_60fab62910fa449ba95eb8532c1020e6&rfr_iscdi=true |